EUVIMEDOdkrijte EUVIMED
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen access · CC BY-NC-ND 4.0

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study

Evaluation eines oralen Small-Molecule-GLP-1-Rezeptoragonisten lotiglipron bei Typ-2-Diabetes und Adipositas: dosisfindende Phase-2-Studie mit Randomisierung und Placebokontrolle

Neeta B Amin, Robert Frederich, Nikolaos Tsamandouras, Amina Z Haggag, Tilman Schuster, Witold Zmuda, Alexandra Palmer, Szilard Vasas, Gina Buckley, Timothy R Smith, Sarah J DuBrava, Qi Zhu and 1 more

Diabetes, Obesity and Metabolism · 2025-01 · 27 (1) · 215-227

DOI: 10.1111/dom.16005 ↗

Auf einen Blick

Lotiglipron senkte bei Typ-2-Diabetes HbA1c und bei Adipositas das Körpergewicht. Die Studie wurde aus Sicherheitsgründen vorzeitig beendet.

Fragestellung

Wirkung und Sicherheit von lotiglipron bei Menschen mit Typ-2-Diabetes oder Adipositas.

Methode

Phase-2-Studie, randomisiert, doppelblind, placebokontrolliert, dosisfindend; vorzeitiger Stopp aus Sicherheitsgründen nach Daten- und Monitoringprüfung.

Ergebnisse

901 Teilnehmende erhielten mindestens 1 Dosis (T2D n=512; Adipositas n=389). HbA1c sank in der T2D-Kohorte bis −1,44 % (90 %-KI −1,63 bis −1,26) vs. −0,07 % mit Placebo. Gewicht sank bis −7,47 % (90 %-KI −8,50 bis −6,43) vs. −1,84 % mit Placebo.

Einschränkungen

Mehrheit der randomisierten Personen mit höheren Dosen erreichte die Zielerhaltungsdosis nicht; geplante Endpunktanalysen vor Entblindung geändert; Studie vorzeitig beendet.

Schlussfolgerung der Autor:innen

Die Wirksamkeit von lotiglipron bei T2D und Adipositas wurde gezeigt. Wegen unerwarteter Transaminasenerhöhungen und fehlender Identifikation einer Risikogruppe wurde die klinische Entwicklung beendet.

Kernaussagen

  • HbA1c sank bei T2D in allen Lotiglipron-Dosen
  • Körpergewicht sank bei Adipositas in allen Lotiglipron-Dosen
  • Gastrointestinale Nebenwirkungen und Transaminasenerhöhungen traten auf

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Klinische Studie (Phase II) in Diabetes, Obesity and Metabolism, published online on 2024-10-16. Written by Neeta B Amin and 12 co-authors. Institution: Internal Medicine, Pfizer Research & Development, Cambridge, Massachusetts, USA. Major MEDLINE topics: Diabetes Mellitus, Type 2, Obesity, Hypoglycemic Agents, Glycated Hemoglobin. Cited 37 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Pfizer.

Auf einen BlickPovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Aim

The aim was to investigate the effects of lotiglipron, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in participants with type 2 diabetes (T2D) or obesity. Materials and Methods A phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study investigated the efficacy and safety of lotiglipron. The study was terminated early for safety reasons after routine data and monitoring review. The planned analyses for the end points were modified prior to unblinding the study.

Results

In total, 901 participants were treated with at least one dose of the study drug (T2D cohort: n = 512, obesity cohort: n = 389). Although the majority of participants who were randomly assigned to higher doses did not reach their target maintenance dose, statistically significant changes in HbA1c and body weight were observed. In the T2D cohort, reductions in HbA1c were observed across all lotiglipron doses at week 16 ( p < 0.0001), with least squares mean decreases up to −1.44% (90% confidence interval [CI]: −1.63, −1.26) (lotiglipron 80 mg), versus placebo, −0.07% (90% CI: −0.25, 0.11). In the obesity cohort, decreases in body weight were observed across all lotiglipron doses at week 20 ( p < 0.01), up to −7.47% (90% CI: −8.50, −6.43) (lotiglipron 200 mg, five‐step titration), versus placebo, −1.84% (90% CI: −2.85, −0.83). Across cohorts, the most frequently reported treatment‐emergent adverse events were gastrointestinal related (most mild to moderate severity), with nausea being the most common (ranging from 4% [placebo] to 28.8% [80 mg] in the T2D cohort and 12.5% [placebo] to 60.6% [200 mg, four‐step titration] in the obesity cohort). Transaminase elevations were observed in a subset of participants (6.6% and 6.0% of participants on lotiglipron in the T2D and obesity cohorts, respectively, compared with 1.6% on placebo in the obesity cohort).

Conclusions

The efficacy (HbA1c and/or body weight) of a range of lotiglipron doses was demonstrated in T2D and obesity cohorts. The safety profile was largely consistent with what has been previously known about the mechanism of action. Our results are unique in reporting elevations in liver transaminases in a subset of participants treated with lotiglipron, with attempts to identify the at‐risk population unsuccessful and therefore clinical development of lotiglipron terminated. ClinicalTrials.gov NCT05579977.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2ObesityHypoglycemic AgentsGlycated HemoglobinDose-Response Relationship, DrugGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleFemaleDouble-Blind MethodMiddle AgedAdultAgedGlucagon-Like Peptide 1Treatment OutcomeAdministration, OralBlood Glucose

Author keywords

HbA1cPF‐07081532diabetesglucagon‐like peptide‐1 receptor agonistlotiglipronobesityphase 2 studyweight loss

Substances

Hypoglycemic AgentsGlycated HemoglobinGlucagon-Like Peptide 1hemoglobin A1c protein, humanrGLP-1 proteinBlood GlucoseGlucagon-Like Peptide-1 Receptor Agonists

Authors and institutions

  • Internal Medicine, Pfizer Research & Development, Cambridge, Massachusetts, USA.
  • Clinical Development and Operations, Pfizer Research & Development, Groton, Connecticut, USA.
  • Clinical Pharmacology, Pfizer Research & Development, Cambridge, Massachusetts, USA.
  • Anaheim Clinical Trials, Anaheim, California, USA.
  • Clinical Development and Operations, Pfizer Research & Development, Cambridge, Massachusetts, USA.
  • Medicome Sp. Z O.O., Oświęcim, Poland.

Funding

  • Pfizer

Cite

APA

Amin, N. B., Frederich, R., Tsamandouras, N., Haggag, A. Z., Schuster, T., Zmuda, W., Palmer, A., Vasas, S., Buckley, G., Smith, T. R., DuBrava, S. J., Zhu, Q., & Johnson, M. (2025). Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study. Diabetes, Obesity and Metabolism, 27(1), 215-227. https://doi.org/10.1111/dom.16005

Vancouver

Amin NB, Frederich R, Tsamandouras N, Haggag AZ, Schuster T, Zmuda W, et al. Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study. Diabetes, Obesity and Metabolism. 2025;27(1):215-227. doi:10.1111/dom.16005

BibTeX
@article{Amin2025,
  author = {Amin, Neeta B and Frederich, Robert and Tsamandouras, Nikolaos and Haggag, Amina Z and Schuster, Tilman and Zmuda, Witold and Palmer, Alexandra and Vasas, Szilard and Buckley, Gina and Smith, Timothy R and DuBrava, Sarah J and Zhu, Qi and Johnson, Margot},
  title = {Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {1},
  pages = {215--227},
  doi = {10.1111/dom.16005}
}
Start for free →